Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Treasury Shares (2022 - 2026)

Atea Pharmaceuticals' Treasury Shares history spans 5 years, with the latest figure at $4.0 million for Q1 2026.

  • Quarterly Treasury Shares rose 61.79% to $4.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Mar 2026, up 61.79% year-over-year, with the annual reading at $2.5 million for FY2025, 38.32% up from the prior year.
  • Treasury Shares came in at $4.0 million for Q1 2026, up from $2.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $4.0 million in Q1 2026 to a low of $724970.0 in Q4 2022.
  • The 5-year median for Treasury Shares is $2.3 million (2023), against an average of $2.2 million.
  • The largest YoY upside for Treasury Shares was 145.92% in 2024 against a maximum downside of 23.73% in 2024.
  • Atea Pharmaceuticals' Treasury Shares stood at $724970.0 in 2022, then changed by 0.0% to $724970.0 in 2023, then soared by 145.92% to $1.8 million in 2024, then surged by 38.32% to $2.5 million in 2025, then surged by 61.79% to $4.0 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Treasury Shares are $4.0 million (Q1 2026), $2.5 million (Q4 2025), and $3.1 million (Q3 2025).